Pharma News

Scientists have identified a genetic flaw responsible for a rare form of inherited allergy induced by vibration.Running, hand clapping, towel drying or even taking a bumpy bus ride can cause temporary skin rashes in people with this rare disorder, also known as vibratory urticaria.

The Council for Scientific and Industrial Research (CSIR) on Wednesday launched BGR-34  the country's first anti-diabetic ayurvedic drug designed for Type-2 diabetes mellitus which has been scientifically validated for its efficacy and safety.

Hyderabad-based Bharat Biotech is developing world's first vaccine for Zika virus, which has been declared as public health emergency by the World Health Organisation.

Due to dietary factors, humans are taller now but taller people are more prone to the risk of cancer, warns a recent study.The taller people, though have lower risk for heart disease and Type-2 diabetes, said the study carried out by researchers in Germany.

An Indian-origin researcher is developing a low-cost, portable device to detect tainted medicines and food supplements that otherwise can make their way to consumers.

Being diagnosed with cancer at a prime age with flying dreams and a family to look after can be earth-shattering for most people. But when it comes to facing the stark reality, whom does one blame for the slow but certain decay of cells and tissues in your body.

The United Nations Children' s Fund (UNICEF) on Tuesday called for immediate action to help stop the spread of Zika virus which is the suspected underlying cause of soaring cases of microcephaly in newborn babies in Brazil.

Dr. Reddy's Lab (DRL) has received tentative approval from the US health regulator for anti-biotic Zenavod indicated for the treatment of a type of chronic skin disease in adult patients.

[adsense:336x280:8701650588]

Allergan plc. , a leading global pharmaceutical company  announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for adjunctive treatment of Major Depressive Disorder (MDD). This follows the Fast Track Designation for rapastinel granted by the FDA in 2014.

MabVax Therapeutics Holdings, Inc., announces receipt of notice from the U.S. Food and Drug Administration (FDA) authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.  The Company filed an Investigational New Drug (IND) application for this trial with the FDA on December 29, 2015.  MabVax previously announced receipt of FDA authorization for a Phase I trial with HuMab-5B1 as a therapeutic treatment for patients with pancreatic cancer, and patient enrollment in both Phase I trials is expected to commence in the first quarter of 2016.